Volume 10, Number 10—October 2004
Research
Disease Susceptibility to ST11 Complex Meningococci Bearing Serogroup C or W135 Polysaccharide Capsules, North America1
Andrew J. Pollard*
, Jan Ochnio†, Margaret Ho†, Martin Callaghan*, Mark Bigham‡, and Simon Dobson†
, Jan Ochnio†, Margaret Ho†, Martin Callaghan*, Mark Bigham‡, and Simon Dobson†
Figure 1
Figure 1. Incidence (cases/100,000/year) of meningococcal disease (average rates 1985–2000) in relation to serogroup C and W135 bactericidal antibody titers in British Columbia against a local ST11 outbreak isolate (AOBZ1379) and Z1582/FC978 (a Canadian clinical isolate from 2000 bearing the W135 capsule), respectively.
1These data were partially presented as a poster at the International Pathogenic Neisseria Conference in Oslo, Norway, 2002.
Page created: April 11, 2011
Page updated: April 11, 2011
Page reviewed: April 11, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.